These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8806176)

  • 1. The E6 variant proteins E6I-E6IV of human papillomavirus 16: expression in cell free systems and bacteria and study of their interaction with p53.
    Shally M; Alloul N; Jackman A; Muller M; Gissmann L; Sherman L
    Virus Res; 1996 Jun; 42(1-2):81-96. PubMed ID: 8806176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
    Pim D; Massimi P; Banks L
    Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus type 18 E6*, E6, and E7 protein synthesis in cell-free translation systems and comparison of E6 and E7 in vitro translation products to proteins immunoprecipitated from human epithelial cells.
    Roggenbuck B; Larsen PM; Fey SJ; Bartsch D; Gissmann L; Schwarz E
    J Virol; 1991 Sep; 65(9):5068-72. PubMed ID: 1651423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins.
    Scheffner M; Takahashi T; Huibregtse JM; Minna JD; Howley PM
    J Virol; 1992 Aug; 66(8):5100-5. PubMed ID: 1321290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
    Crook T; Tidy JA; Vousden KH
    Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins.
    Scheffner M; Münger K; Huibregtse JM; Howley PM
    EMBO J; 1992 Jul; 11(7):2425-31. PubMed ID: 1321031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation.
    Li X; Coffino P
    J Virol; 1996 Jul; 70(7):4509-16. PubMed ID: 8676476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16.
    Sherman L; Schlegel R
    J Virol; 1996 May; 70(5):3269-79. PubMed ID: 8627810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
    Scheffner M; Werness BA; Huibregtse JM; Levine AJ; Howley PM
    Cell; 1990 Dec; 63(6):1129-36. PubMed ID: 2175676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
    Mansur CP; Marcus B; Dalal S; Androphy EJ
    Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of p53 DNA binding by human papillomavirus E6 proteins.
    Lechner MS; Laimins LA
    J Virol; 1994 Jul; 68(7):4262-73. PubMed ID: 8207801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.
    Giovane C; Trave G; Briones A; Lutz Y; Wasylyk B; Weiss E
    J Mol Recognit; 1999; 12(2):141-52. PubMed ID: 10398405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.
    Huibregtse JM; Scheffner M; Howley PM
    EMBO J; 1991 Dec; 10(13):4129-35. PubMed ID: 1661671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
    Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53.
    Huibregtse JM; Scheffner M; Howley PM
    Mol Cell Biol; 1993 Feb; 13(2):775-84. PubMed ID: 8380895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.
    Zimmermann H; Degenkolbe R; Bernard HU; O'Connor MJ
    J Virol; 1999 Aug; 73(8):6209-19. PubMed ID: 10400710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.
    Lagrange M; Charbonnier S; Orfanoudakis G; Robinson P; Zanier K; Masson M; Lutz Y; Trave G; Weiss E; Deryckere F
    J Gen Virol; 2005 Apr; 86(Pt 4):1001-1007. PubMed ID: 15784893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest.
    Foster SA; Demers GW; Etscheid BG; Galloway DA
    J Virol; 1994 Sep; 68(9):5698-705. PubMed ID: 8057451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular analysis of the interaction between HPV type 16 E6 and human E6-associated protein.
    Daniels PR; Sanders CM; Coulson P; Maitland NJ
    FEBS Lett; 1997 Oct; 416(1):6-10. PubMed ID: 9369221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
    Pim D; Banks L
    Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.